EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Connective tissue disease‐associated pulmonary hypertension: A comprehensive review

Vikramjit Khangoora, Elana J Bernstein, Christopher S King iD, Oksana A Shlobin

Pulmonary Circulation · 2023-10 · 13 (4)

DOI: 10.1002/pul2.12276 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pulmonary Circulation, online erschienen am 11.12.2023. Verfasst von Vikramjit Khangoora und 3 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Lung Disease and Transplant Program Inova Fairfax Hospital Falls Church Virginia USA. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Connective tissue diseases (CTDs) can be associated with various forms of pulmonary hypertension, including pulmonary arterial hypertension (PAH), pulmonary veno‐occlusive disease, pulmonary venous hypertension, interstitial lung disease‐associated pulmonary hypertension, chronic thromboembolic pulmonary hypertension, and sometimes a combination of several processes. The prevalence of PAH varies among the different CTDs, with systemic sclerosis (SSc) having the highest at 8%–12%. The most recent European Society of Cardiology/European Respiratory Society guidelines recommend routine annual screening for PAH in SSc and CTDs with SSc features. As CTDs can be associated with a myriad of presentations of pulmonary hypertension, a thorough evaluation to include a right heart catheterization to clearly delineate the hemodynamic profile is essential in developing an appropriate treatment plan. Treatment strategies will depend on the predominant phenotype of pulmonary vasculopathy. In general, management approach to CTD‐PAH mirrors that of idiopathic PAH. Despite this, outcomes of CTD‐PAH are inferior to those of idiopathic PAH, with those of SSc‐PAH being particularly poor. Reasons for this may include extrapulmonary manifestations of CTDs, including renal disease and gastrointestinal involvement, concurrent interstitial lung disease, and differences in the innate response of the right ventricle to increased pulmonary vascular resistance. Early referral for lung transplant evaluation of patients with CTD‐PAH, particularly SSc‐PAH, is recommended. It is hoped that in the near future, additional therapies may be added to the armamentarium of effective treatments for CTD‐PAH. Ultimately, a better understanding of the pathogenesis of CTD‐PAH will be required to develop targeted therapies for this morbid condition.

Schlagwörter

Stichwörter der Autor:innen

connective tissue diseasepulmonary arterial hypertensionpulmonary hypertensionsclerodermasystemic lupus erythematosus

Autor:innen und Institutionen

  • Advanced Lung Disease and Transplant Program Inova Fairfax Hospital Falls Church Virginia USA.
  • Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons Columbia University Irving Medical Center New York New York USA.

ORCID-Profile: Christopher S King

Zitieren

APA

Khangoora, V., Bernstein, E. J., King, C. S., & Shlobin, O. A. (2023). Connective tissue disease‐associated pulmonary hypertension: A comprehensive review. Pulmonary Circulation, 13(4). https://doi.org/10.1002/pul2.12276

Vancouver

Khangoora V, Bernstein EJ, King CS, Shlobin OA. Connective tissue disease‐associated pulmonary hypertension: A comprehensive review. Pulmonary Circulation. 2023;13(4). doi:10.1002/pul2.12276

BibTeX
@article{Khangoora2023,
  author = {Khangoora, Vikramjit and Bernstein, Elana J and King, Christopher S and Shlobin, Oksana A},
  title = {Connective tissue disease‐associated pulmonary hypertension: A comprehensive review},
  journal = {Pulmonary Circulation},
  year = {2023},
  volume = {13},
  number = {4},
  doi = {10.1002/pul2.12276}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche